BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T051452
CREATED:20200917T132624Z
LAST-MODIFIED:20200917T132919Z
UID:27122-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:4th Annual Antifibrotic Drug Development Summit
DESCRIPTION:Solving the Translational Drug Development Gap\, From Fibrotic Mechanisms to Clinically Effective Therapeutics. \nNow in its 4th year\, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights\, AFDD will bridge the current translational gap to anti-fibrotic drug development success \nJoin 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs. \nTo know more about 4th Annual Antifibrotic Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-antifibrotic-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T051452
CREATED:20201021T154020Z
LAST-MODIFIED:20201022T115845Z
UID:27582-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:3rd Lifecycle Management for Combination Products Summit
DESCRIPTION:The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development\, to CMC and regulatory affairs\, our experts speakers will help you delve into how to produce a quality and safe combination product\, implications of EU MDR and the final implementation phase of post-market surveillance reporting. \nTo know more about 3rd Lifecycle Management for Combination Products Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-lifecycle-management-for-combination-products-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T051452
CREATED:20200910T131817Z
LAST-MODIFIED:20200917T152111Z
UID:26980-1605571200-1605743999@www.pharmajournalist.com
SUMMARY:Clinical Operations in Oncology Trials USA 2020: Virtual Conference
DESCRIPTION:As the industry grapples with unprecedented challenges\, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology\, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.\n\nTo know more about Clinical Operations in Oncology Trials USA 2020 please click here.
URL:https://www.pharmajournalist.com/event/clinical-operations-in-oncology-trials-usa-2020-virtual-conference/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201120
DTSTAMP:20260515T051452
CREATED:20200923T134148Z
LAST-MODIFIED:20200923T134148Z
UID:27221-1605571200-1605830399@www.pharmajournalist.com
SUMMARY:CRISPR 2.0
DESCRIPTION:Discover the Next Generation of CRISPR Tools to Enhance Specificity\, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality \nCRISPR is one of the most powerful discoveries of the last decade. \nIn a remarkably short space of time\, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox\, which leads to the question: what’s next? \nCRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology\, from the potential of prime editing through to epigenome editing to treat chronic pain. \nDon’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools. \nJoin us to usher in the next generation of safe\, targeted and effective genome editing. \nFor more information on the conference\, visit https://ter.li/ok8ifs \n“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman\, Past attendee\, CRISPR Event Series \n” I greatly enjoyed the diversity and topic coverage of the talks\, thanks for putting together an excellent program!” Christina Kolodzy\, Past attendee\, CRISPR Event Series \n “A high-quality worthwhile conference\, attended by first rate professionals. I learned more than I anticipated I would” Past attendee\, CRISPR Event Series
URL:https://www.pharmajournalist.com/event/crispr-2-0/
LOCATION:Digital Congress
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T051452
CREATED:20200930T094828Z
LAST-MODIFIED:20210118T080755Z
UID:27309-1605657600-1608335999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December\, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th\, allowing you to do business in China\, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nCPhI & P-MEC China Virtual Expo Connect\nA hybrid offline-2-online platform for global pharma professionals\nNov 18 – Dec 18\, 2020 \nTo know more about CPhI & P-MEC China Virtual Expo Connect please click here.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect/
LOCATION:Virtual Event powered by CPhI China & Pharmasources.com
CATEGORIES:e
ORGANIZER;CN="CPhI China & Pharmasources.com":MAILTO:yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T051452
CREATED:20200422T095652Z
LAST-MODIFIED:20200605T104633Z
UID:25145-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:Digital Pathology & AI Congress: USA
DESCRIPTION:This meeting has a reputation for providing an outstanding networking experience. Discover how to effectively harness gains such as reducing lab costs\, improving links with other laboratories and scientists\, and minimizing human error. \n \nTopics covered on the agenda include: \n\nHow AI is being applied to primary diagnosis and clinical research.\nAI for image analysis and advancements in imaging\nComputational pathology and AI\nImplementation: practicalities and costs\nPharma and industry case studies\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/digital-pathology-ai-congress-usa/
LOCATION:New York\, USA\, United States
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T051452
CREATED:20200423T110625Z
LAST-MODIFIED:20200423T110625Z
UID:25215-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:Women and Infant Health Microbiome Congress
DESCRIPTION:With dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/women-and-infant-health-microbiome-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T051452
CREATED:20200731T092307Z
LAST-MODIFIED:20200731T092307Z
UID:26532-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:Digital Agenda Revealed: 9th HPAPI Summit
DESCRIPTION:As the world around us evolves\, we want to ensure we can still unite you and your peers in highly potent API development and manufacturing. \nWe are excited to have transformed the 9th HPAPI Summit into a fully digital meeting running on November 19-20.  \nThanks to our dedicated speakers\, we’re still able to deliver the high-quality content and networking opportunities that you need to advance your high potent strategy in your company\, from development to containment to EHS and outsourcing. \nAnd the best part? As a giving back to our long standing HPAPI community\, pharma\, biotech and academia can now register for free! \nSolution provider rate starts from $1\,259\, register by August 7 to save up to $280. \nDownload the new digital event program here. \nHere’s a glimpse at some of the expert speakers confirmed to present: \n\nChristopher Sears\, Senior Director\, CMC Tarveda Therapeutics\nCornelia Rudolph\, Clean Water DG Environment\, European Commission\nGraeme McKilligan\, Lead Senior GMDP Inspector\, MHRA\nMirjam Sax\, Principal Site Manager\, Genentech\nDave Eherts\, Vice President Global EHS\, Allergan\nAndrew Hopkins\, Director\, Operation Quality\, QA Audit & Compliance\, AbbVie\nJohn Roosa\, Director\, New Technology Development & Industrial Hygiene Engineer\, Merck\n\nOur bespoke virtual conference platform will allow you to network with industry colleagues\, evaluate new suppliers and the latest technology HPAPI containment and participate in live Q&A with speakers. For more details see here. \nWe hope to see you there!
URL:https://www.pharmajournalist.com/event/digital-agenda-revealed-9th-hpapi-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T051452
CREATED:20201008T102355Z
LAST-MODIFIED:20201008T102858Z
UID:27406-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:In-House Impact: Life Sciences 2020 – Virtual Event
DESCRIPTION:Redefining In-House Counsel as Innovator & Strategic Partner\, Maximizing & Benchmarking Legal Business Value to Set the New Standard for Today’s Life Sciences Lawyer. \nIn-House Impact works because it connects you with the most forward-thinking legal leaders taking the most radical steps to maximize the business value they add as strategic business partners. \nWith thought-provoking case studies\, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers\, we guarantee that your time and your money are well spent. \nThis conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences. \nWe believe the traditional conference format is no longer fit for purpose\, so we started from scratch. \n \nHere’s how it works: \nWhen you look at the event agenda\, you will see three main types of sessions: \n\nDiscover sessions offer you the chance to hear the boldest legal leaders in Life Sciences sharing the stories of what they’re doing to maximize the impact of their team\nDevelop sessions provide you with the unique opportunity to have your burning questions answered in a room full of your peers and move beyond the ‘what’ and the ‘why’ to get to the ‘how’\nAction sessions divide the audience by same-level seniority\, and are designed to help you discuss challenges with peers\, and decide what you are going to change in order to add as much value to the business\n\nIn-House Impact: Life Sciences is a new event\, both designed by and for General Counsels of Life Sciences companies\, from smaller start-ups to large pharmaceuticals. \nFor more information visit https://ter.li/cata3o\, or contact the team via email at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/in-house-impact-life-sciences-2020-virtual-event/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201124
DTEND;VALUE=DATE:20201125
DTSTAMP:20260515T051452
CREATED:20200910T133510Z
LAST-MODIFIED:20200917T152233Z
UID:26983-1606176000-1606262399@www.pharmajournalist.com
SUMMARY:*NEW* Translating Documentation & Communication Clinical Research: Virtual Conference
DESCRIPTION:This one-day online event will deliver top-quality content and engagement covering all aspects of language operations for clinical research: clinical trial protocols\, informed consent\, site documents\, regulatory submissions and correspondence\, labeling\, IFUs\, patient correspondence\, and much more.\n \nTo know more about Translating Documentation & Communication Clinical Research please click here.
URL:https://www.pharmajournalist.com/event/new-translating-documentation-communication-clinical-research-virtual-conference/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201126
DTEND;VALUE=DATE:20201127
DTSTAMP:20260515T051452
CREATED:20201103T111452Z
LAST-MODIFIED:20201103T111452Z
UID:27752-1606348800-1606435199@www.pharmajournalist.com
SUMMARY:Cost-efficient and Green Manufacturing of Peptides thanks to Molecular Hiving™ Technology
DESCRIPTION:HOSTED BY: Bachem Group\nLED BY: Dr. Wolfgang Seufert\, Director Production III – Process Development\, Bachem \nBachem and Jitsubo CO.\, Ltd. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s Molecular Hiving™ Technology. Under the License agreement\, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ Technology and transfer these processes to Bachem. Bachem will further optimize\, scale up and produce for commercial applications. \n \nMolecular Hiving™ is a tag-assisted liquid-phase peptide synthesis technology developed by Professor Kazuhiro Chiba at Tokyo University of Technology and Agriculture. This technology uses a hydrophobic tag\, which is applied in the same way as the resin for solid-phase peptide synthesis (SPPS) processes. The same standard Fmoc amino acid derivatives as for SPPS are applied for assembling the peptide chain. However\, all couplings and cleavages of the Fmoc protecting group are performed in solution allowing for fast reactions and direct in-process controls\, e.g. by HPLC. Excess reagents as well as coupling and cleavage related by-products are solely removed by aqueous extractions. Therefore\, intermediate isolation of the tag-bound peptide and excessive washing steps are not required for Molecular Hiving™ Technology. \nIn this webinar\, the speaker will guide you through the individual steps for synthesis of peptides applying Molecular Hiving™ Technology. You will learn about the scalability and the substantial advantages of this technology regarding efficiency and towards greener manufacturing\, as solvent consumption and material requirements are significantly reduced compared to conventional SPPS processes. Molecular Hiving™ also allows the synthesis of peptides without the use of solvents and reagents which are carcinogenic\, mutagenic\, or toxic to reproduction (CMR substances). This makes peptide products manufactured by this technology highly attractive for the pharmaceutical and cosmetics industry. \nBenefits for Joining the Webinar: \n\nHear about Bachem’s partnership with Jitsubo\nDiscover how to synthesize peptides by Molecular Hiving™ Technology\nExplore the advantages and the environmental benefits of Molecular Hiving™ Technology\nLearn about manufacture of peptides without CMR solvents and reagents\n\nWho should attend? \nScientists in Pharma\, Biotech\, Cosmetics industry\, and Universities including: \n\nResearch Scientists and Associates\nPostDocs and PhDs\nScientific Advisors\nDirectors of Research and Development\n\nOther Professionals in the Life Sciences including Product Managers and Marketing Managers
URL:https://www.pharmajournalist.com/event/cost-efficient-and-green-manufacturing-of-peptides-thanks-to-molecular-hiving-technology/
LOCATION:Online Webinar
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201130
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T051452
CREATED:20200715T082010Z
LAST-MODIFIED:20200817T082502Z
UID:26329-1606694400-1607039999@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Analytical Development | Running Digitally for 2020
DESCRIPTION:Optimizing Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of rapid gene therapy progress and mounting regulatory scrutiny\, the 2nd Annual Gene Therapy Analytical Development Summit will virtually unite large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific conference will unite the Analytical Development\, QC\, CMC\, and Process Development leaders grappling with these challenges first-hand. \nIncorporating tracks taking a deep dive into bioassays\, molecular biology\, and analytical chemistry\, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you’re encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo know more about 2nd Annual Gene Therapy Analytical Development please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-analytical-development/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T051452
CREATED:20200826T084509Z
LAST-MODIFIED:20200826T093822Z
UID:26843-1606780800-1607039999@www.pharmajournalist.com
SUMMARY:2nd RNA Editing Summit 2020
DESCRIPTION:RNA Editing is reaching an inflection point and is rapidly being discussed\, invested in and adopted by the industry. \nThis year\, in an all new digital format\, the timely 2nd RNA Editing Summit returns as the only industry led meeting showcasing the recent developments of RNA editing mechanisms and dedicated to realizing the research and therapeutic opportunity of RNA editing as quickly as possible. \n \nThis meeting offers a wealth of relevant content covering everything from basic RNA biology and the fundamentals of RNA editing through to mitigating against off target activity to the plethora of clinical applications. \nJoin industry leaders from the likes of InsideOutBio\, Edigene\, Locano Bio and more to: \n\nHear the current strategies of site directed RNA editing from A – I to C – U to CRISPR based\nUnderstand how to mitigate off target-activity without critically effecting the efficiency of the on target edit in the transcript\nEnsure the safety and stability of your edit whilst maintaining efficiency and safe guard against potential toxic events\nAssess how to develop RNA editing technologies in preclinical models to ensure the system works as intended in the human body\nDelve into the different delivery mechanisms available to ensure the protein molecules that do the editing make it into the cells\nIdentify the latest clinical applications of RNA Editing\, reviewing the structures and functions of ADARs\, CRISPR CAS 13\, APOBEC and their involvements in human diseases\n\nTo know more about 2nd RNA Editing Summit 2020 please click here.
URL:https://www.pharmajournalist.com/event/2nd-rna-editing-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201203
DTSTAMP:20260515T051452
CREATED:20200930T082606Z
LAST-MODIFIED:20200930T082606Z
UID:27304-1606780800-1606953599@www.pharmajournalist.com
SUMMARY:Neuromuscular Drug Development Summit
DESCRIPTION:Validate Clinically Meaningful Endpoints\, Optimize Clinical Trial Design & Compare & Contrast Diverse Approaches to Accelerate the Discovery & Development of Meaningful Treatments for Patients in Need \n \nThe 3rd Neuromuscular Drug Development  Summit presents a unique opportunity to: \n\nUncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen\nHear approaches to optimizing therapeutic efficacy in SMA\, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche\, PTC Therapeutics and John Hopkins University School of Medicine\nAssess emerging neurophysiological methods for more quantitative\, faster readouts and the need to explore digital capture tools to improve therapeutic R&D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD)\nDissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose\, mechanisms of action and endpoints with NMD Pharma and Argenx\nEvaluate the role of biomarkers\, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institut\nHear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1\n\nUniting drug developers and academics from all corners of the world\, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field\, convey lessons learned and network to build long lasting partnerships.
URL:https://www.pharmajournalist.com/event/neuromuscular-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T051452
CREATED:20200423T111553Z
LAST-MODIFIED:20200423T111553Z
UID:25220-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:7th Microbiome & Probiotics R&D & Business Collaboration Forum: Europe
DESCRIPTION:In response to COVID-19\, this meeting will be hosted online using the latest digital technology. Network with your peers\, ask questions of the speakers\, and meet with the sponsors from the safety of your home or office. \nThis forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products. \nTopics covered on the agenda include: \n\nIBD\, Colitis\, and Metabolic Diseases\nGut-brain axis\nWomen’s health\nSkin & Cosmeceuticals\nPersonalized nutrition\nBusiness Collaboration – Regulations & Investment\nProbiotics & Prebiotics\nRoundtable discussions\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-microbiome-probiotics-rd-business-collaboration-forum-europe/
LOCATION:Rotterdam\, The Netherlands
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T051452
CREATED:20200828T083254Z
LAST-MODIFIED:20200828T083616Z
UID:26875-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:Clinically Validated Digital Therapeutics Summit
DESCRIPTION:As the world opens up to digital health\, now is the time to design\, develop & deliver clinically validated digital therapeutics to patients in need. Back for its 3rd year\, the Clinically Validated Digital Therapeutics Summit will unite more stakeholders than ever before. Explore newcomers in the world of DTx\, showcasing never before shared case studies. This meeting will solely focus on the actionable uses of digital therapeutics to deliver radically improved patient outcomes. \nIntegrating brand new lessons learned from the COVID 19 pandemic\, the 2020 summit will drive the DTx industry forward with case studies that tackle a multitude of disease areas and therapeutic modalities\, from prescription and chronic disease management to care bundles\, concomitant therapy and preventive medicine. Covering the full spectrum\, the 2020 summit will address challenges around clinical trials\, regulatory approval\, reimbursement and value application in healthcare. \nView the Full Event Guide Here.
URL:https://www.pharmajournalist.com/event/clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201203
DTEND;VALUE=DATE:20201205
DTSTAMP:20260515T051452
CREATED:20200423T112329Z
LAST-MODIFIED:20200605T110454Z
UID:25224-1606953600-1607126399@www.pharmajournalist.com
SUMMARY:7th Digital Pathology & AI Congress: Europe
DESCRIPTION:This meeting has a reputation for providing an outstanding networking experience in which you can discover how to effectively harness gains such as reducing lab costs\, improving links between other laboratories & scientists and minimizing human error. \n \nOver two days you will discover more about the latest advances and applications of digital pathology\, including: \n\nHow artificial intelligence and machine learning is being applied to primary diagnosis and clinical research.\nHow the image-based information environment is transforming the laboratory.\nAI for image analysis and advancements in imaging.\nComputational pathology and AI.\nImplementation: practicalities and costs.\nPharma and industry case studies.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-digital-pathology-ai-congress-europe/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T051452
CREATED:20200217T121202Z
LAST-MODIFIED:20201123T131643Z
UID:24217-1607299200-1607644799@www.pharmajournalist.com
SUMMARY:BioFIT 2020
DESCRIPTION:Come and join us online for the 9th edition of BioFIT\, from the 7th to the 10th of December 2020! \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \n \nKEY FIGURES: \n\n1\,400+ delegates\n900+ organisations\n40+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\nConferences and roundtable discussions\nOral presentations of start-ups and licensing opportunities stemming from academia\nAn exhibition area\nInformal networking evenings\n\nAcross these 4 days of event\, you will be able to e-meet and network with these attendees from the comfort of your home office. The one-to-one partnering meetings will be possible 24H a day. \nYou will also have access\, for the conferences and the pitch sessions\, to a mix of live and on-demand content during those 4 days and available for 30 days afterwards; and you will also have the opportunity to debate with the speakers and pitchers via interactive online chats. \nWebsite: www.biofit-event.com \nRegistration: www.biofit-event.com/registration-for-biofit/ \nContact: msatola@eurasante.com
URL:https://www.pharmajournalist.com/event/biofit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Eurasant%C3%A9%2C Clubster NHL%2C BioValley France and Eurobiomed":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T051452
CREATED:20200817T090658Z
LAST-MODIFIED:20200817T090658Z
UID:26779-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
DESCRIPTION:Revolutionize the Development & Delivery of Neurological Gene Therapies  \nReturning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer\, Biogen\, Voyager and Novartis\, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges\, enabling you to accelerate the development of your neurological gene therapy candidate. \nDon’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS\, optimize translational modelling approaches and discover targeted\, efficacious\, and safe vectors to revolutionize the treatment of neurological disorders. \nTo learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-for-neurological-disorders-running-digitally-for-2020/
LOCATION:Vitual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T051452
CREATED:20200819T090705Z
LAST-MODIFIED:20200819T090705Z
UID:26807-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field\, such as successful determination and prediction of RNA structure and role in disease\, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development. \n \nWith numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules\, join leading biopharmaceutical directors\, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes. \nThe world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA\, opening the door to RNA targeted small molecule drug discovery. \n  \n  \n\nExplore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute\, Anima Biotech & Arrakis Therapeutics\n\n  \n\nSuccessfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics\, Accent Therapeutics & Saverna Therapeutics\n\n  \n\nExpand your knowledge of RNA structure\, function & role in disease with insights from Yale University\, H3 Biomedicine & Whitehead Institute for Biomedical Research\n\n  \n\nAdvance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University\n\n  \n\nOvercome binding\, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche\, University of California San Diego & Novartis\n\n \nTo know more about 3rd RNA-Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201210
DTSTAMP:20260515T051452
CREATED:20201020T131537Z
LAST-MODIFIED:20201020T131537Z
UID:27562-1607385600-1607558399@www.pharmajournalist.com
SUMMARY:Decentralized Clinical Trails Summit
DESCRIPTION:Strengthen Your Operational and Compliance Protocols to Accelerate Technology-Enabled\, Patient-Centric\, and Cost-Efficient Decentralized Clinical Trials \nWith the potential to improve recruitment rates\, simplify compliance\, reduce drop-out rates\, and speed-up your product’s time to market\, decentralized clinical trials represent an opportunity to rethink and refresh how research studies are conducted\, while keeping the patient at the heart of all trials. \n \nDespite this\, only a fraction of clinical trials are currently run as hybrid of virtual models. This is about to change. The age of decentralized clinical trials is here\, and keeping pace with the rest of the industry means preparing your internal processes for the change. \nCreated in conjunction with clinical trial leaders from big and small pharma\,  forward thinking  academics\, and research institutes\, the programme for this year’s Decentralized Clinical summit has been designed to help you to develop the toolkit you need to run successful decentralised trials. Join over 100+ peers this December to tackle issues such as: using digital tools and wearables\, maintaining data quality and integrity\, simplifying e-consent\, optimising patient recruitment\, restructuring project teams\, rethinking trial design and undertaking study-model matching. \nTo know more about Decentralized Clinical Trails Summit please click here.
URL:https://www.pharmajournalist.com/event/decentralized-clinical-trails-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T051452
CREATED:20201026T092432Z
LAST-MODIFIED:20201026T092432Z
UID:27669-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:As the tools and technologies that are available to study the skin microbiome become cheaper and more accessible\, the fundamental mechanisms that link the skin microbiome with skin health are becoming stronger. The demand for skin microbiome products is advancing rapidly which is only being reflected in the increasing number of products on the market that claim to modulate the microbiome. \nDespite this growing opportunity\, there are still a number of basic and clinical science that need addressing to ensure that industry researchers are creating products that demonstrate true impact in patients and consumers. \n \nThe 3rd Microbiome Movement ­– Skin Health & Dermatology Summit returns to unite leaders from academia and industry to address the unique challenges that working within the skin microbiome possesses\, with the goal to accelerate microbiome-targeted therapeutics and cosmetics. \nWith discussions focusing on targeting the microbiome to treat inflammatory skin disease\, exploring how pre\, pro and post biotics can be optimized to improve skin health as well as a view into the regulatory and patent landscape; this opportunity is not to be missed. This is not to mention our new Pre-Conference Commercialization & Marketing Focus Day that will provide a deep dive into consumer education and product differentiation. \nTo know more about 3rd Microbiome Movement – Skin Health & Dermatology Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201209
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T051452
CREATED:20191030T073844Z
LAST-MODIFIED:20200923T084604Z
UID:23096-1607472000-1608335999@www.pharmajournalist.com
SUMMARY:Medical Fair Asia 2020 Digital Edition
DESCRIPTION:MEDICAL FAIR ASIA 2020 Digital Edition is set to take place from 9 – 18 December 2020. The shift to a digital event for its 13th edition is in response to the dynamic situation of the COVID-19 pandemic\, where travel and physical restrictions are still in effect globally. \n \nAs the leading medical and healthcare exhibition in the region\, the well-established exhibition will feature the latest medical technology and innovations\, and healthcare equipment and supplies for the Hospital\, Diagnostics\, Pharmaceutical\, Medical & Rehabilitation sectors. \nMoving from in-person interactions at a physical trade event to making virtual connections anywhere in the world\, MEDICAL FAIR ASIA Digital Edition aims to deliver the onsite benefits of a trade fair but with all the convenience of an online experience. \nMEDICAL FAIR ASIA is organised by Messe Düsseldorf Asia\, the subsidiary of Messe Düsseldorf GmbH based in Germany and organiser of the world’s no. 1 medical fair – MEDICA. The exhibition is also a member of the MEDICAlliance\, the global network for medical trade fairs worldwide. \nFor more information about Medical Fair Asia 2020 and to register\, visit https://www.medicalfair-asia.com/
URL:https://www.pharmajournalist.com/event/medical-fair-asia-2020/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Messe Duesseldorf Asia":MAILTO:medicalfair-asia@mda.com.sg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210113
DTEND;VALUE=DATE:20210115
DTSTAMP:20260515T051452
CREATED:20200910T124837Z
LAST-MODIFIED:20201015T100412Z
UID:26969-1610496000-1610668799@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices 2021
DESCRIPTION:Device design\, regulatory and strategic pathways for parenteral drug delivery \nSMi is proud to present the 13th Annual Pre-Filled Syringes Conference on 13th and 14th January 2021. \nThe pre-filled syringes industry is growing at an exponential rate. With increasing demand for self-administration\, a rise in biologics\, large-volume delivery and the delayed EU MDR at the forefront of the field\, SMi’s 13th annual event will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry. \nTopics of discussion will include the latest updates on the EU MDR and Article 117\, advances in novel drug products and biologics\, parenteral packaging for pre-filled syringes\, innovations in device design and platforms for combination products\, lifecycle management and much more… \n \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nAs Europe’s first Pre-Filled Syringes Conference of 2021\, this event is not to be missed. We look forward to welcoming you to the conference in January. \nBENEFITS OF ATTENDING:  \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nView the full agenda and speaker line-up online: www.pre-filled-syringes.com/pjwl \nPlus\, pre-conference workshops will be taking place on 12th January : \nWorkshop A: Digital Health – What are the real-world opportunities and potential barriers to adoption?\nWorkshop Leader: Andrew Dundon\, Founder\, PharMechceutics Ltd\n08.30 – 12.00  \nWorkshop B: Challenges and Drivers for Development of Long Acting Injectables\nWorkshop Leader: Joël Richard\, Chief Development Officer\, MedinCell\n13.00 – 17.00 \nEARLY-BIRD RATES: \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\nBOOK BY 30TH OCTOBER AND SAVE £200\nBOOK BY 30TH NOVEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.pre-filled-syringes.com/pjwl \nChairs for 2020: \n\nBjørg Kaae Hunter\, Department Manager\, RA CMC & Device; RA NextGen Drug-Device\,\nNovo Nordisk\nAlphons Fakler\, Head Medical Device Risk Management\, Novartis\n\nFeatured speakers:  \n\nBrian Holly\, Head of Human Factors\, Devices Centre of Excellence\, Pfizer \nDaniel Latham\, Head Device Development & LCM\, Novartis \nRene Holm\, Head and Scientifi c Director\, Drug Product Development\, Liquids and Parenterals\, Janssen\nStefano Martini\, Responsible for Special Programs\, Medical Devices Development\, Sanofi \nSarah Tang\, Regulatory Affairs Manager\, Devices Division\, MHRA \nAbha Raveau violette\, Device Manager\, AstraZeneca \nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck \nJulia Frese\, Director\, TÜV SÜD\nClemens Günther\, Director\, Senior Expert Nonclinical Safety\, Bayer \nJonathan Sutch\, Technical Specialist\, BSI\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nFollow us:  @SMiPharm #PFSSMi
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210120
DTEND;VALUE=DATE:20210122
DTSTAMP:20260515T051452
CREATED:20201117T084847Z
LAST-MODIFIED:20201117T084847Z
UID:27957-1611100800-1611273599@www.pharmajournalist.com
SUMMARY:Onco Cell Therapy Global
DESCRIPTION:Following the success of our first digital event in July with the likes of Carl June leading the keynote\, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations\, townhall meetings\, roundtable sessions and coffee break style networking. \n \nThe Global Onco Cell Therapy Summit is an online event\, 20th – 21st January 2021\, that provides a platform for information sharing to enable the discovery\, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma\, biotechs and academia. The summit will address the research\, regulatory\, logistical and technical challenges that are holding back the field. \nDelve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through: \n\nMeeting efficacies and safety targets as well as the scale of demands.\nDiscovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.\nOvercoming the challenging in scale up and automation of manufacturing\nRound table discussions on vectors and the promise of non-viral approaches.\nReimbursement strategies and their link to the latest developments in safety trials and regulatory standards\n\nWhilst bringing together the key decision makers for oncological cell therapies\, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments. \nNew for 2020 | Pre-event sessions: \n25th Nov | Manufacturing roundtable | FREE to attend \n15th Dec | ASH Review | FREE to attend \n19th Jan | NK Day | Registrants only \nVisit the website www.oncocelltherapyglobal.com for more details and to view the full agenda. (link to https://go.kisacoresearch.com/l/678123/2020-11-16/4r1xv). Don’t forget as a reader of Pharma Journalist\, quote PJ10 for a 10% discount.
URL:https://www.pharmajournalist.com/event/onco-cell-therapy-global/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T051452
CREATED:20201027T084532Z
LAST-MODIFIED:20201027T084532Z
UID:27681-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:TGFβ for Immuno-Oncology Drug Development Summit
DESCRIPTION:The world of TGFβ is at a tipping point within industry\, for an explosion of data to come.  \nExploring the wide array of approaches being utilized in pharma\, biotech\, and academia\, the TGFβ for Immuno-Oncology Drug Development Summit is the ONLY industry-led event dedicated exclusively to exploring TGF-beta’s role in cancer therapeutics. This 3-day summit is your definitive meeting to delve into the core challenges of this complex target.  \n \nDon’t miss out on your chance to deepen your understanding of cell signaling mechanisms\, change your view of the tumor microenvironment\, and prepare your candidates for the clinic to ensure patient safety.   \nJoin your peers this year to: \n\nHear from Scholar Rock on the selective inhibition of TGFβ1 activation with SRK-181\, their phase 1 candidate  \nDiscover the latest on Bintrafusp Alfa clinical trials from James Gulley at NCI\, and Clinical Development from Yan Lan at EMD Serono \n\n\nExplore the mechanism of action data from Novartis on their anti-transforming growth factor-beta antibody XOMA089 \nGet involved in Takeda\, Scholar Rock\, Oncotelic\, and Sanofi’s debate the best TGF-beta isoform to target\, combination vs monotherapy approaches\, and the winning therapeutic approach  \nContrast Small Molecule vs Antibody approaches to utilizing Integrin Inhibition with presentations from Morphic Therapeutic and Venn Therapeutics  \n\n To know more about TGFβ for Immuno-Oncology Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/tgf%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T051452
CREATED:20201204T104141Z
LAST-MODIFIED:20201204T104141Z
UID:28158-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:4th Antigen Specific Immune Tolerance Summit (ASIT)
DESCRIPTION:The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n \nThis is the industry’s definitive antigen specific drug development forum. \nAcross 3 packed days\, thought leaders from Novartis\, ImCyse\, Harvard Medical School\, Toleranzia\, Toralgen will reveal insight\, data\, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders. \nTo know more about 4th Antigen Specific Immune Tolerance Summit (ASIT) please click here.
URL:https://www.pharmajournalist.com/event/4th-antigen-specific-immune-tolerance-summit-asit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210209
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T051452
CREATED:20201022T101624Z
LAST-MODIFIED:20201022T104507Z
UID:27586-1612828800-1613087999@www.pharmajournalist.com
SUMMARY:Gene Therapy Medical Affairs
DESCRIPTION:The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients. \nIndustry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy\, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies. \n \nJoin this definitive\, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nThis virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement\, discussion\, and Q&A’s in order for you to get the best value from this meeting. \nTo know more about Gene Therapy Medical Affairs please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-medical-affairs/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T051452
CREATED:20201001T101330Z
LAST-MODIFIED:20201019T092845Z
UID:27319-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:RNA Therapeutics 2021
DESCRIPTION:Innovations in technologies and applications of RNA-based medicine \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. Furthermore\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, have triggered a major expansion of the RNA-therapeutics field. \nThe 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies\, oligonucleotide delivery\, therapeutic applications and future trends and innovations. \n \nJoin us in February 2021\, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry\, upcoming regulatory updates and industry implications. \nBENEFITS OF ATTENDING:  \n\nExplore in industry insights into how mRNA is being used to combat COVID-19\nEngage in case studies exploring the growing therapeutic potential of RNA for rare diseases\nDelve into future trends in AI application for optimal RNA therapeutics\nHear regulatory outlooks of the RNA landscape\, clinical trials and looking ahead\n\nView the full agenda and speaker line-up online: www.therapeutics-rna.com/pjwl \nFocus day on RNA Interference – 12TH February 2021\n\nAs the industry of RNA therapeutics advances this year’s focus day will explore the growing potential of RNA interference. The focus day will present sessions that explore the evolving approaches to RNAi including: antifibrotic microRNA-based therapeutics for the treatment of Alport syndrome\, self-deliverable RNAi and an exploration into how siRNA can be modified for self-delivery\, and targeted delivery of nucleic acid therapeutics. Furthermore\, this year’s focus day will be highlighting the emerging trends and future outlook of RNAi in the Pharmaceutical industry. \nEARLY-BIRD RATES:  \n\nBOOK BY 30TH OCTOBER AND SAVE £400\nBOOK BY 30TH NOVEMBER AND SAVE £200\nBOOK BY 11TH DECEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.therapeutics-rna.com/pjwl \nChairs for 2021: \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFocus Day Chair for 2021: Shalini Andersson\, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery\, AstraZeneca \nFeatured speakers:  \n\nDong Yu\, Fellow\, Senior Director\, and Head\, GSK Vaccines\nMaria Luisa Pineda\, CEO and Co-Founder\, Envisagenics\nKirsty Wydenbach\, Deputy Unit Manager/Senior Medical Assessor\, MHRA\nDong Ki Lee\, CEO\, OliX\nJennifer Pluim\, Vice President Medical Affairs\, ProQR\nArpan Desai\, Team Leader\, Advanced Drug Delivery\, Pharmaceutical Sciences\, AstraZeneca\nRuchi Shah\, Senior Research Engineer\, New Therapeutics Modalities\, Eli Lilly and Company\nMichael Mulqueen\, Vice President Business Development\, eTheRNA immunotherapies\nTroels Koch\, Founder & CEO\, Aqiventa\n\nWho should attend: \n\nResearch & Development Directors/Managers/Scientists\nHeads of Clinical Development\nHeads of Pre-Clinical Development\nHead of RNA Biology\nHead of RNA Formulation and Drug Delivery\nHead of Pre-clinical R&D\nHead of New Modalities\nHead of Discovery\nSenior Scientists\nChief Scientific Officers\nChief Medical Officers\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nFollow us:  @SMiPharm #SMirna
URL:https://www.pharmajournalist.com/event/rna-therapeutics-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T051452
CREATED:20201012T114728Z
LAST-MODIFIED:20201012T114728Z
UID:27476-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:Sponsored by: Celvivo \nChaired by: Stefan Przyborski\, Professor of Cell Technology\, Durham University \nDeveloping Complex Physiologically Relevant Cell Models in Vitro \n3D Cell Culture is gaining momentum in the pharmaceutical industry\, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery\, predictivity and validation\, safety\, and toxicity. \n \nSMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development\, toxicity testing\, and safety assurance. In addition\, the conference will look into the newest breakthroughs in Organ Chip technology\, 3D Multicellular scaffolding\, Microphysiological Systems\, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application. \nEvent Hashtag: #SMi3DCellCulture \nHIGHLIGHTS FOR 2021 \n\nDiscover the cutting-edge technology that is changing the face of pharmaceutical drug development\nExplore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives\nInsight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro\nDiscuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery\nAssess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops\n\nFEATURED SPEAKERS INCLUDE: \n\nSuzanne Fitzpatrick\, Senior Advisor for Toxicology\, US Food and Drug Administration\nPelin Candarlioglu\, Investigator – Bioengineer/Cell Biologist\, GSK\nRobert Vries\, CEO\, Hubrecht organoid Technology\nSakshi Garg\, Lab Head\, Discovery & Development Technologies\, Merck Group\nRhiannon David\, Scientific Lead Microphysiological Systems\, AstraZeneca\nStephen J. fey\, Founder and Chief Research Officer\, CelVivo\nAlejandro Amador\, Director\, Cellular Assays and Technologies\, Incyte\nFreddy Van Goethem\, Scientific Director – Fellow\, Predictive\, Investigative\, and Translational Toxicology\, Johnson & Johnson; Janssen Pharmaceutical\nJulian Bahr\, Postdoctoral Fellow\, Oncology\, AstraZeneca\nPedro Pinto\, Laboratory Manager\, Urology\, university of Greifswald – Medical Centre\n\nView the full agenda: www.3D-cellculture.com/PJwl \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist Academia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering Solution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR